Readily3D
Readily3D develops and commercializes the Tomolite volumetric 3D printer, which can fabricate complex biological models and tissues in under 30 seconds.
- CEO / Founder
- Paul Delrot
- Team Size
- 1-10
- Stage
- Commercial
- Total Funding
- $3.08M
- Latest Round
- Grant
- Key Investors
- Horizon Europe, Venture Kick, MassChallenge Switzerland, EIT Health
Technology & Products
Key Products
["Tomolite 3D Printer","Apparite Software","READYPCL INX (Polyester-based resin, in partnership with BIO INX)","READY-GEL INX (Gelatin-based resin, in partnership with BIO INX)"]
Technological Advantage
The primary advantage is speed and cell viability. Printing a centimeter-scale biological structure in seconds, rather than hours, significantly improves the feasibility of creating complex tissues with living cells. This speed, combined with the cell-friendly nature of the process, opens up new possibilities for drug testing models, regenerative medicine, and fundamental biological research.
Differentiation
Value Proposition
To enable the printing of complex, cell-laden biological structures at an unprecedented speed (seconds vs. hours) with high cell viability, overcoming the limitations of traditional layer-by-layer bioprinting.
How They Differentiate
Readily3D differentiates itself fundamentally through its core technology. While competitors primarily use extrusion-based or layer-by-layer stereolithography (SLA) methods, Readily3D's volumetric approach is orders of magnitude faster and gentler on cells. This allows for the creation of more complex and delicate structures that are not feasible with other techniques, positioning them at the high-end, pioneering segment of the market.
Market & Competition
Target Customers
Academic and medical research laboratories, pharmaceutical companies, and organizations focused on tissue engineering and regenerative medicine.
Industry Verticals
["Biotechnology Research","Pharmaceuticals","Regenerative Medicine","Medical Research"]
Competitors
BICO Group (formerly CELLINK); Organovo; 3D Systems (Allevi)
Growth & Milestones
Major Milestones
["Spun-off from EPFL in 2020.","Launched the Tomolite volumetric bioprinter.","Secured funding and participation in the €3.6M ENLIGHT project to 3D print a human pancreas.","Established a key commercial partnership with BIO INX to launch new biomaterials (2024).","Awarded funding from Venture Kick."]
Notable Customers
University Medical Center (UMC) Utrecht; Swiss Federal Institute of Technology in Lausanne (EPFL)